These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34105142)

  • 41. [The Lymphoid Variant of HES (L-HES) as Differential Diagnose of Severe Asthma in Childhood].
    Leu T; Rauthe S; Wirth C; Simon HU; Kunzmann V; Hebestreit H; Kunzmann S
    Klin Padiatr; 2016 Nov; 228(6-07):319-324. PubMed ID: 27846662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
    Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U
    Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The hypereosinophilic syndromes: still more heterogeneity.
    Gleich GJ; Leiferman KM
    Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
    Roufosse F; Goldman M; Cogan E
    Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical overview of cutaneous features in hypereosinophilic syndrome.
    Plötz SG; Hüttig B; Aigner B; Merkel C; Brockow K; Akdis C; Darsow U; Ring J
    Curr Allergy Asthma Rep; 2012 Apr; 12(2):85-98. PubMed ID: 22359067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell clonality in hypereosinophilic syndrome: what pathogenetic role?
    Galimberti S; Ciabatti E; Ottimo F; Rossi A; Trombi L; Carulli G; Cervetti G; Matti L; Bianchi G; Petrini M
    Clin Exp Rheumatol; 2007; 25(1):17-22. PubMed ID: 17417985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
    Schaller JL; Burkland GA
    MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
    Harish A; Schwartz SA
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
    Roufosse FE; Kahn JE; Gleich GJ; Schwartz LB; Singh AD; Rosenwasser LJ; Denburg JA; Ring J; Rothenberg ME; Sheikh J; Haig AE; Mallett SA; Templeton DN; Ortega HG; Klion AD
    J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.
    Butterfield JH
    Acta Haematol; 2005; 114(1):26-40. PubMed ID: 15995323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How I treat hypereosinophilic syndromes.
    Klion AD
    Blood; 2009 Oct; 114(18):3736-41. PubMed ID: 19692700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypereosinophilic syndromes.
    Roufosse FE; Goldman M; Cogan E
    Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.
    Butterfield JH
    Leuk Res; 2009 Aug; 33(8):1127-9. PubMed ID: 19144405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
    Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB
    Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome.
    Choi C; Moller D; Tan J; Dou C; Peterson EA; Medvedev N; Dutz JP; Carruthers MN; Chen LYC
    Br J Haematol; 2020 Mar; 188(5):e68-e72. PubMed ID: 31721154
    [No Abstract]   [Full Text] [Related]  

  • 60. What we have learned about lymphocytic variant hypereosinophilic syndrome: A systematic literature review.
    Shi Y; Wang C
    Clin Immunol; 2022 Apr; 237():108982. PubMed ID: 35307610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.